GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

How long does Ozempic stay in your system? What to expect after stopping, including clearance time, side effects, and factors that influence it.

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

As a mass rollout of weight loss injections begins across the NHS, with GPs able to prescribe Mounjaro for the first time ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

Mounjaro was launched in India earlier this year, while many leading multinational pharma companies are in the race to ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal antibody that binds to and inhibits activin receptor type-2B, with semaglutide ...

As India becomes the new and latest nation witnessing the for weight-loss drugs frenzy, Novo Nordisk’s Wegovy challenges Eli ...

More than one in four UK adults are obese, but only a small number will be eligible for the latest treatment from the NHS ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

UnitedHealthcare, CVS Health’s Aetna and dozens of other insurers say they plan to reduce the scope of health care claims ...